Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Inzucchi SE, Khunti K, Fitchett DH, Wanner C, et al. Cardiovascular (CV) Benefit of Empagliflozin Across the Spectrum of CV Risk Factor Control in the EMPA-REG OUTCOME Trial. J Clin Endocrinol Metab 2020 Jun 2. pii: 5850548. doi: 10.1210.
PMID: 32485734


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016